Allogene Therapeutics (ALLO) Operating Leases (2018 - 2026)

Allogene Therapeutics (ALLO) has 9 years of Operating Leases data on file, last reported at $81.1 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 8.85% year-over-year to $81.1 million; the trailing twelve-month figure through Mar 2026 stood at $81.1 million (down 8.85% YoY), and the FY2025 full-year result was $83.3 million, down 8.27% from the prior year.
• Operating Leases fell to $81.1 million in Q1 2026, from $83.3 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $98.2 million in Q2 2022 to a low of $69.0 million in Q1 2022.
• A 5-year average of $88.1 million and a median of $90.1 million in 2023 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases surged 91.83% in 2022 and fell 15.89% in 2025, its largest moves.
• Tracing ALLO's Operating Leases over 5 years: stood at $95.1 million in 2022, then retreated by 0.0% to $95.1 million in 2023, then slipped by 4.59% to $90.8 million in 2024, then slipped by 8.27% to $83.3 million in 2025, then slipped by 2.64% to $81.1 million in 2026.
• Business Quant data shows ALLO's Operating Leases at $81.1 million in Q1 2026, $83.3 million in Q4 2025, and $77.1 million in Q3 2025.